Altimmune Inc. Common Stock (ALT)
Stock · NASDAQ · Health Care
$2.2as of 10/16/2026
Price chart
Active signals
ALT Signal Track Record
How signals performed across all stocks →What ALT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -1.1% | 47% | September 18, 2026 |
| Bollinger Band Breakout | 22 | -1.9% | 36% | August 25, 2026 |
| Bollinger Band Breakdown | 17 | +8.8% | 65% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -6.5% | 38% | February 12, 2026 |
| Any 20-session window (baseline) | -3.5% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 57
- Website
- altimmune.com/
Fundamentals
- 1-day range
- $2.71$2.81
- Market cap
- $585.37M
- P/E (trailing)
- —
- P/E (forward)
- -4.09
- EPS (trailing)
- $-0.78
- Dividend yield
- —
- Beta
- 0.06
- Avg. volume
- 4.15M
- Ex-dividend date
- January 20, 2017
- Dividend pay date
- September 14, 2018
How Altimmune Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 6, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Altimmune Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.08$6.13$13.02
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.08 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Altimmune Details Pemvidutide’s Path Toward a Liver-Disease FranchiseYahoo · 10/1/2026
- Altimmune to Participate in Stifel Cardiometabolic ForumYahoo · 9/23/2026
- Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17Benzinga · 9/23/2026
- VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’Yahoo · 9/22/2026
- Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?Yahoo · 9/11/2026
Insider Activity
Insider Actions →- MENZIUSO RICHARD THOMAS · October 1, 2026 · Grant36.2K
- MENZIUSO RICHARD THOMAS · October 1, 2026 · Grant84.5K
- Richardson Linda M · September 16, 2026 · Option Exercise24.0K
- Richardson Linda M · September 16, 2026 · Tax Withholding6.8K @ $3.24
- Jerome Benedict Durso · August 13, 2026 · Buy15.0K @ $2.95
- M. Scot Roberts · July 31, 2026 · Grant875 @ $2.41
- Gregory L. Weaver · July 31, 2026 · Grant1.8K @ $2.41
- Wayne Pisano · May 1, 2026 · Grant48.8K
- Hodges Philip · May 1, 2026 · Grant48.8K
- Diane Jorkasky · May 1, 2026 · Grant48.8K
- Lawver Teri L · May 1, 2026 · Grant48.8K
- Schafer Klaus · May 1, 2026 · Grant48.8K
- Catherine A. Sohn · May 1, 2026 · Grant48.8K
- John Gill · May 1, 2026 · Grant48.8K
- SAYARE MITCHEL · May 1, 2026 · Grant48.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 64.90M
- Total value held
- $198.52M
- Institutional holders
- 167
- Unknown12.80M
- Unknown7.15M
- Unknown5.66M
- Unknown4.02M
- Unknown3.26M
- Unknown3.11M
- Unknown2.64M
- Unknown2.48M
- Unknown2.44M
- Unknown2.33M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.